Heart failure is a major global health problem with unmet therapeutic requirements despite the development of neurohormonal modulators for systolic heart failure. In this Review, the authors discuss the evidence resulting from clinical trials of novel pharmacological agents targeting contractility, neurohormonal signalling, vasodilatation, renal preservation, inflammation, and myocardial protection.
- Thomas G. von Lueder
- Henry Krum